Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of BNT323 versus investigator's choice chemotherapy in previously treated HER2-expressing recurrent endometrial cancer
MOH_2025-11-23_015485Phase 3Not yet recruiting
- Sponsor
- BioNTech SE
- Start
- Nov 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab pamirtecan, doxorubicin and paclitaxel in endometrial cancer (EC) (2 arms), sponsored by BioNTech SE. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
trastuzumab pamirtecandoxorubicinpaclitaxel
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on MOH_2025-11-23_015485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-23_015485.